Analysts expect Natus Medical Inc (NASDAQ:BABY) to report sales of $132.92 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Natus Medical’s earnings. The highest sales estimate is $133.40 million and the lowest is $132.50 million. Natus Medical reported sales of $122.64 million during the same quarter last year, which indicates a positive year-over-year growth rate of 8.4%. The company is scheduled to issue its next quarterly earnings results on Wednesday, October 24th.
On average, analysts expect that Natus Medical will report full year sales of $530.21 million for the current year, with estimates ranging from $529.00 million to $531.54 million. For the next fiscal year, analysts expect that the company will report sales of $547.80 million, with estimates ranging from $540.70 million to $557.79 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Natus Medical.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, July 25th. The medical equipment provider reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.09. The firm had revenue of $130.70 million for the quarter, compared to analyst estimates of $130.60 million. Natus Medical had a negative net margin of 4.16% and a positive return on equity of 11.18%. Natus Medical’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.34 EPS.
Several analysts recently issued reports on the stock. BidaskClub upgraded shares of Natus Medical from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, August 10th. Finally, ValuEngine upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $44.33.
BABY traded down $0.10 on Friday, hitting $34.95. The company had a trading volume of 146,500 shares, compared to its average volume of 357,857. The firm has a market cap of $1.17 billion, a P/E ratio of 24.10 and a beta of 0.60. Natus Medical has a 1 year low of $28.00 and a 1 year high of $43.60. The company has a current ratio of 2.99, a quick ratio of 2.19 and a debt-to-equity ratio of 0.29.
In other Natus Medical news, Director Ken Ludlum sold 8,000 shares of Natus Medical stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $36.89, for a total value of $295,120.00. Following the completion of the transaction, the director now directly owns 98,957 shares of the company’s stock, valued at approximately $3,650,523.73. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Robert A. Gunst sold 9,100 shares of Natus Medical stock in a transaction dated Friday, July 27th. The shares were sold at an average price of $34.11, for a total value of $310,401.00. Following the completion of the transaction, the director now directly owns 54,982 shares of the company’s stock, valued at $1,875,436.02. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 77,540 shares of company stock valued at $2,804,615. 5.50% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in Natus Medical in the 1st quarter valued at about $124,000. US Bancorp DE grew its position in Natus Medical by 81.2% in the 1st quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 2,125 shares in the last quarter. Sei Investments Co. grew its position in Natus Medical by 46.3% in the 2nd quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock valued at $161,000 after acquiring an additional 1,478 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Natus Medical by 1,010.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,132 shares of the medical equipment provider’s stock valued at $177,000 after acquiring an additional 4,670 shares in the last quarter. Finally, Xact Kapitalforvaltning AB acquired a new position in Natus Medical in the 2nd quarter valued at about $201,000. 96.88% of the stock is owned by institutional investors.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.